Syosset, NY - The Science of Neurogenetics in Addiction Therapy
Description:
Complimentary dinner & presentation hosted by Nancy Hilsenrath, Treatment Placement Specialists®, and Accutox Medical Diagnostic
Presented by: Justin Jones
Date: Wednesday, July 10, 2019
Dinner & Presentation: 6:00-8:30 p.m.
Location:
Chris & Tony's
352 Jericho Turnpike
Syosset, NY 11791
Neuro-Genetics and Addiction:
The science of Neuro-genetics is being propelled into the forefront as a more analytical and novel approach to addiction treatment. Once such approach that is getting a tremendous amount of interest by healthcare organizations is the treatment of neuro-genetics.
Certain genes potentially impact how well an individual can control substance and non-substance addictive behaviors including cravings. Approximately 50% of your overall risk for addiction is genetic. The reward pathway underlying addiction is well documented. Neuroscientists now understand that natural sequence variation within each gene underpinning the brain reward cascade can contribute to a person’s unique total addiction risk. Certain known genetic variations (termed “risk variations”) are now clearly linked to an increased risk of developing addictive behaviors.
Scientific evidence suggests that your genetic risk for Reward Deficiency Syndrome (RDS) is directly correlated to how many of these addiction risk variations you carry. Substantial neuroscience research links drug use and related disorders with specific genes and genetic variants; alcohol, heroin, cocaine, nicotine, and narcotic abuse, along with other addictive behaviors like overeating, gambling, online gaming, and aberrant sexual activity.
Polygenic complexes of genes drive most of our heredity-based actions, suggesting that genetic panels or algorithms organized into genetic indexes, such as a Genetic Addiction Risk Score (GARS) may be valuable clinically to determine risk. Understanding that the abnormal functions of these brain systems can be due to specific genetic factors interacting with the environment leading to epigeneticeffects is likely to lead to better treatment.
About our Speaker:
Justin Jones - CEO and Board Member of Geneus Health
Justin Jones is a graduate of Texas State University with a M.B.A. from Post University Malcolm Baldridge School of Business. Justin has 19 years of experience in executive management, marketing, mergers and acquisitions, and many other roles with both Fortune 500 and small, specialized companies including Dr. Pepper/7-UP, ICOS Biotech, Cangene Biopharma, Jazz Pharmaceuticals, Advanced Genomics, and Geneus Health.
Justin also has a diverse business background in both the U.S. and internationally, including China, Bahrain, South Africa, Canada, Mexico, Japan, Turkey, and the United Kingdom. As CEO of Advanced Genomics, he structured a partnership with CTI, the largest publically traded laboratory company in China, to develop a pharmacogenetic testing division. As CEO of Geneus Health, he led the company to obtain the first ever patent on a genetic test in U.S. history.
He currently or has previously held board member positions with both business and charitable organizations, including the Texas Adolescent Young Adult Oncology Conference, Driscoll Children’s Hospital Chemo Kids, San Antonio Childhood Cancer Survivors Coalition, Rays of Relief, Avagen Health, Kalypso Wellness Centers, and Geneus Health.
Justin is a published author of the Powerhouse Interviewing Workbook. Along his career, Justin invented and patented an innovative liquid dispensing product. The product and company were sold in 2011. In his free time Justin enjoys spending time with his wife and three children, and playing basketball.
RSVP Information:
This is a free event, but an RSVP is required by completing the form below. If you have any questions, please contact Nancy Hilsenrath at Nancy.Hilsenrath@acadiahealthcare.com or call/text (516) 316-7657.
We are sorry but registration for this event is now closed.
Please contact us if you would like to know if spaces are still available.
